Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion
Rev. bras. hematol. hemoter
; 35(6): 428-434, 2013. tab, graf
Article
en En
| LILACS
| ID: lil-699988
Biblioteca responsable:
BR408.1
ABSTRACT
In the absence of an iron chelating agent, patients with beta-thalassemia on regular transfusions present complications of transfusion-related iron overload. Without iron chelation therapy, heart disease is the major cause of death; however, hepatic and endocrine complications also occur. Currently there are three iron chelating agents available for continuous use in patients with thalassemia on regular transfusions (desferrioxamine, deferiprone, and deferasirox) providing good results in reducing cardiac, hepatic and endocrine toxicity. These practice guidelines, prepared by the Scientific Committee of Associação Brasileira de Thalassemia (ABRASTA), presents a review of the literature regarding iron overload assessment (by imaging and laboratory exams) and the role of T2* magnetic resonance imaging (MRI) to control iron overload and iron chelation therapy, with evidence-based recommendations for each clinical situation. Based on this review, the authors propose an iron chelation protocol for patients with thalassemia under regular transfusions.
Palabras clave
Texto completo:
1
Índice:
LILACS
Asunto principal:
Transfusión Sanguínea
/
Imagen por Resonancia Magnética
/
Terapia por Quelación
/
Protocolos Clínicos
/
Quelantes del Hierro
/
Talasemia beta
/
Trastornos del Metabolismo del Hierro
Tipo de estudio:
Guideline
/
Risk_factors_studies
Límite:
Humans
País/Región como asunto:
America do sul
/
Brasil
Idioma:
En
Revista:
Rev. bras. hematol. hemoter
Asunto de la revista:
HEMATOLOGIA
Año:
2013
Tipo del documento:
Article